These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 31411214)

  • 1. Exploration of HIV-1 fusion peptide-antibody VRC34.01 binding reveals fundamental neutralization sites.
    Feng M; Bell DR; Kang H; Shao Q; Zhou R
    Phys Chem Chem Phys; 2019 Aug; 21(34):18569-18576. PubMed ID: 31411214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.
    Kong R; Xu K; Zhou T; Acharya P; Lemmin T; Liu K; Ozorowski G; Soto C; Taft JD; Bailer RT; Cale EM; Chen L; Choi CW; Chuang GY; Doria-Rose NA; Druz A; Georgiev IS; Gorman J; Huang J; Joyce MG; Louder MK; Ma X; McKee K; O'Dell S; Pancera M; Yang Y; Blanchard SC; Mothes W; Burton DR; Koff WC; Connors M; Ward AB; Kwong PD; Mascola JR
    Science; 2016 May; 352(6287):828-33. PubMed ID: 27174988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural and Thermodynamic Basis of Epitope Binding by Neutralizing and Nonneutralizing Forms of the Anti-HIV-1 Antibody 4E10.
    Rujas E; Gulzar N; Morante K; Tsumoto K; Scott JK; Nieva JL; Caaveiro JM
    J Virol; 2015 Dec; 89(23):11975-89. PubMed ID: 26378169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage.
    Shen CH; DeKosky BJ; Guo Y; Xu K; Gu Y; Kilam D; Ko SH; Kong R; Liu K; Louder MK; Ou L; Zhang B; Chao CW; Corcoran MM; Feng E; Huang J; Normandin E; O'Dell S; Ransier A; Rawi R; Sastry M; Schmidt SD; Wang S; Wang Y; Chuang GY; Doria-Rose NA; Lin B; Zhou T; Boritz EA; Connors M; Douek DC; Karlsson Hedestam GB; Sheng Z; Shapiro L; Mascola JR; Kwong PD
    Cell Host Microbe; 2020 Apr; 27(4):531-543.e6. PubMed ID: 32130953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
    Keller PW; Morrison O; Vassell R; Weiss CD
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure of the HIV-1 broadly neutralizing antibody 10E8 MPER epitope on the membrane surface by gp41 transmembrane domain scaffolds.
    Oakes V; Torralba J; Rujas E; Nieva JL; Domene C; Apellaniz B
    Biochim Biophys Acta Biomembr; 2018 Jun; 1860(6):1259-1271. PubMed ID: 29477358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.
    Maeso R; Huarte N; Julien JP; Kunert R; Pai EF; Nieva JL
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):863-76. PubMed ID: 21142698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential HIV-1 fusion inhibitors mimicking gp41-specific broadly neutralizing antibody 10E8: In silico discovery and prediction of antiviral potency.
    Andrianov AM; Kashyn IA; Tuzikov AV
    J Bioinform Comput Biol; 2018 Apr; 16(2):1840007. PubMed ID: 29439644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV.
    Dingens AS; Acharya P; Haddox HK; Rawi R; Xu K; Chuang GY; Wei H; Zhang B; Mascola JR; Carragher B; Potter CS; Overbaugh J; Kwong PD; Bloom JD
    PLoS Pathog; 2018 Jul; 14(7):e1007159. PubMed ID: 29975771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41.
    Cardoso RM; Zwick MB; Stanfield RL; Kunert R; Binley JM; Katinger H; Burton DR; Wilson IA
    Immunity; 2005 Feb; 22(2):163-73. PubMed ID: 15723805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for broad neutralization of HIV-1 through the molecular recognition of 10E8 helical epitope at the membrane interface.
    Rujas E; Caaveiro JM; Partida-Hanon A; Gulzar N; Morante K; Apellániz B; García-Porras M; Bruix M; Tsumoto K; Scott JK; Jiménez MÁ; Nieva JL
    Sci Rep; 2016 Dec; 6():38177. PubMed ID: 27905530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.
    Finnegan CM; Berg W; Lewis GK; DeVico AL
    J Virol; 2002 Dec; 76(23):12123-34. PubMed ID: 12414953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion.
    Dimitrov AS; Rawat SS; Jiang S; Blumenthal R
    Biochemistry; 2003 Dec; 42(48):14150-8. PubMed ID: 14640682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.
    Phogat S; Svehla K; Tang M; Spadaccini A; Muller J; Mascola J; Berkower I; Wyatt R
    Virology; 2008 Mar; 373(1):72-84. PubMed ID: 18155743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody.
    Luftig MA; Mattu M; Di Giovine P; Geleziunas R; Hrin R; Barbato G; Bianchi E; Miller MD; Pessi A; Carfí A
    Nat Struct Mol Biol; 2006 Aug; 13(8):740-7. PubMed ID: 16862157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions.
    Neurath AR; Strick N; Lin K; Jiang S
    AIDS Res Hum Retroviruses; 1995 Jun; 11(6):687-96. PubMed ID: 7576928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design.
    Irimia A; Serra AM; Sarkar A; Jacak R; Kalyuzhniy O; Sok D; Saye-Francisco KL; Schiffner T; Tingle R; Kubitz M; Adachi Y; Stanfield RL; Deller MC; Burton DR; Schief WR; Wilson IA
    PLoS Pathog; 2017 Feb; 13(2):e1006212. PubMed ID: 28225819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism.
    Ma X; Tan J; Su M; Li C; Zhang X; Wang C
    PLoS One; 2014; 9(11):e111923. PubMed ID: 25393106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide.
    Weissenhorn W; Wharton SA; Calder LJ; Earl PL; Moss B; Aliprandis E; Skehel JJ; Wiley DC
    EMBO J; 1996 Apr; 15(7):1507-14. PubMed ID: 8612573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice.
    Qi Z; Pan C; Lu H; Shui Y; Li L; Li X; Xu X; Liu S; Jiang S
    Biochem Biophys Res Commun; 2010 Jul; 398(3):506-12. PubMed ID: 20599765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.